Literature DB >> 2834869

Interferon treatment inhibits onset of herpes simplex virus immediate-early transcription.

S Mittnacht1, P Straub, H Kirchner, H Jacobsen.   

Abstract

Pretreatment of primary cultures of splenic mouse macrophages with murine IFN-alpha/beta leads to a stable inhibition of herpes simplex virus type 1. Analysis of viral DNA, RNA, and protein synthesis identifies expression of "immediate-early" genes as a major target of IFN-mediated inhibition. Determination of viral DNA in the nuclei early after infection, i.e., before onset of DNA replication, suggests that virus uptake, transport to the nucleus, and DNA stability are not decreased in IFN-pretreated macrophages. Nuclear runoff transcription analysis shows a significant reduction of immediate-early transcription rates following IFN treatment. End-specific probes for the ICP4 gene locate the inhibition to the onset of transcription. Northern blot analysis reveals a decrease in ICP4 transcripts in accordance with the observed inhibition of transcription. The observed inhibition of early gene transcription may be a consequence of decreased immediate-early gene expression.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834869     DOI: 10.1016/0042-6822(88)90637-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells.

Authors:  P Monini; F Carlini; M Stürzl; P Rimessi; F Superti; M Franco; G Melucci-Vigo; A Cafaro; D Goletti; C Sgadari; S Butto'; P Leone; C Chiozzini; C Barresi; A Tinari; A Bonaccorsi; M R Capobianchi; M Giuliani; A di Carlo; M Andreoni; G Rezza; B Ensoli
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication.

Authors:  Karen L Mossman; James R Smiley
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection.

Authors:  Kasey M Eidson; William E Hobbs; Brian J Manning; Paul Carlson; Neal A DeLuca
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 4.  Type I interferons and herpes simplex virus infection: a naked DNA approach as a therapeutic option?

Authors:  S Noisakran; D J Carr
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

5.  Characterization of a potent refractory state and persistence of herpes simplex virus 1 in cell culture.

Authors:  Cristina Barreca; Peter O'Hare
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum.

Authors:  Lianghua Bin; Michael G Edwards; Ryan Heiser; Joanne E Streib; Brittany Richers; Clifton F Hall; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2014-08-23       Impact factor: 10.793

7.  Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: Potential role in blocking IFN-beta induction.

Authors:  Gregory T Melroe; Lindsey Silva; Priscilla A Schaffer; David M Knipe
Journal:  Virology       Date:  2006-11-28       Impact factor: 3.616

8.  Herpes simplex virus-1 infection causes the secretion of a type I interferon-antagonizing protein and inhibits signaling at or before Jak-1 activation.

Authors:  Karen E Johnson; David M Knipe
Journal:  Virology       Date:  2009-10-31       Impact factor: 3.616

9.  Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression.

Authors:  Dmitri G Negorev; Olga V Vladimirova; Alexey Ivanov; Frank Rauscher; Gerd G Maul
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

10.  Regulation of herpes simplex virus thymidine kinase in cells treated with a synergistic antiviral combination of alpha interferon and acyclovir.

Authors:  J L Taylor; P Tom; J Guy; R M Selvarajan; W J O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.